The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotine acetylcholine receptors
Open accessAbstract
Mammalian brain expresses multiple nicotinic acetylcholine receptor (nAChR) subtypes that differ in subunit composition, sites of expression and pharmacological and functional properties. Among known subtypes of receptors, alpha 4 beta 2* and alpha 6 beta 2*-nAChR have the highest affinity for nicotine (where * indicates possibility of other subunits). The alpha 4 beta 2*-nAChRs are widely distributed, while alpha 6 beta 2*-nAChR are restricted to a few regions. Both subtypes modulate release of dopamine from the dopaminergic neurons of the mesoaccumbens pathway thought to be essential for reward and addiction. alpha 4 beta 2*-nAChR also modulate GABA release in these areas. Identification of selective compounds would facilitate study of nAChR subtypes. An improved understanding of the role of nAChR subtypes may help in developing more effective smoking cessation aids with fewer side effects than current therapeutics. We have screened a series of nicotinic compounds that vary in the distance between the pyridine and the cationic center, in steric bulk, and in flexibility of the molecule. These compounds were screened using membrane binding and synaptosomal function assays, or recordings from GH4C1 cells expressing h alpha 7, to determine affinity, potency and efficacy at four subtypes of nAChRs found in brain, alpha 4 beta 2*, alpha 6 beta 2*, alpha 7 and alpha 3 beta 4*. In addition, physiological assays in gain-of-function mutant mice were used to assess in vivo activity at alpha 4 beta 2* and alpha 6 beta 2*-nAChRs. This approach has identified several compounds with agonist or partial agonist activity that display improved selectivity for alpha 6 beta 2*-nAChR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Although ␣62* nAChRs play an important role in addiction, the effect of varenicline on ␣62* nAChR-mediated function in CNS dopaminergic systems is currently unclear”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Grady et al., 2010
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a non-nicotine pharmaceutical currently FDA approved for the treatment of smoking cessation, varenicline, acts as a partial agonist at α6β2* nAChRs (Grady et al. 2010; Bordia et al. 2012).”
From Nicotine Withdrawal (2015) · cites this paper as Grady et al. 2010
In the citing paper
“subsequent work showed that varenicline had a significant effect at ␣7 nAChRs, ␣34* nAChRs, and 5-hydroxytryptamine type 3 receptors”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Grady et al., 2010
In the citing paper
“Work with ␣-CtxMII to delineate the contribution of the ␣62* and ␣42* nAChRs to varenicline-evoked release showed that varenicline was a partial agonist at both subtypes, in agreement with others (Grady et al., 2010).”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Grady et al., 2010
In the citing paper
“It is noteworthy that the binding affinity of varenicline for ␣62* nAChRs was very similar to that of ␣42* nAChRs, in agreement with Grady et al. (2010).”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Grady et al., 2010
In the citing paper
“Thus the mode of interaction of varenicline at ␣62* nAChRs is similar to that at ␣42* nAChRs, as shown here and reported by others (Grady et al., 2010).”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Grady et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
Champtiaux, N., Gotti, C., Cordero‐Erausquin, M., David, D. J. P., Przybylski, C., Léna, C., Clementi, F., Moretti, M., Rossi, F., Novère, N. G. L., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07820.2003 · Cited by 512
Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 401
Self-citationChamptiaux, N., Han, Z., Bessis, A., Rossi, F., Zoli, M., Marubio, L. M., McIntosh, J. M., & Changeux, J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-04-01208.2002 · Cited by 344
Pons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J. M., Changeux, J. P., Maskos, U., & Fratta, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3918-08.2008 · Cited by 312
Hierarchical Control of Dopamine Neuron-Firing Patterns by Nicotinic Receptors
Mameli-Engvall, M., Evrard, A., Pons, S., Maskos, U., Svensson, T. H., Changeux, J.-P., & Faure, P. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.007 · Cited by 296
Cited by
Sorted by citations
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 201
McLaughlin, I., Dani, J. A., & De Biasi, M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/978-3-319-13482-6_4 · Cited by 191
“Indeed, a non-nicotine pharmaceutical currently FDA approved for the treatment of smoking cessation, varenicline, acts as a partial agonist at α6β2* nAChRs (Grady et al. 2010; Bordia et al. 2012).”
Kramer, P. F., Brill-Weil, S. G., Cummins, A. C., Zhang, R., Camacho-Hernandez, G. A., Newman, A. H., Eldridge, M. A. G., Averbeck, B. B., & Khaliq, Z. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.07.011 · Cited by 104
Quik, M., Perez, X. A., & Grady, S. R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.001 · Cited by 97
Self-citationYang, K., Buhlman, L. M., Khan, G. M., Nichols, R. A., Jin, G.-Z., McIntosh, J. M., Whiteaker, P., Lukas, R. J., & Wu, J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3003-10.2011 · Cited by 87
Self-citationNicotine aversion is mediated by GABAergic interpeduncular nucleus inputs to laterodorsal tegmentum
Wolfman, S. L., Gill, D. F., Bogdanic, F., Long, K., Al-Hasani, R., McCall, J. G., Bruchas, M. R., & McGehee, D. S. (2018) · Nature Communications · doi:10.1038/s41467-018-04654-2 · Cited by 81
Igari, M., Alexander, J. C., Ji, Y. R., Qi, X., Papke, R. L., & Bruijnzeel, A. W. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.216 · Cited by 75
Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., & Quik, M. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194852 · Cited by 70
Feduccia, A. A., Simms, J. A., Mill, D., Yi, H. Y., & Bartlett, S. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12690 · Cited by 70
How Menthol Alters Tobacco-Smoking Behavior: A Biological Perspective.
Wickham, R. J. (2015) · PubMed · Cited by 67
Addiction‐related neuroadaptations following chronic nicotine exposure
Wills, L., & Kenny, P. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15356 · Cited by 61
Falk, D. E., Castle, I. P., Ryan, M., Fertig, J. B., & Litten, R. Z. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000133 · Cited by 61
Grady, S. R., Wageman, C. R., Patzlaff, N. E., & Marks, M. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.026 · Cited by 56
Self-citationHillmer, A. T., Li, S., Zheng, M., Scheunemann, M., Lin, S.-F., Nabulsi, N., Holden, D., Pracitto, R., Labaree, D. C., Ropchan, J. R., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3621-8 · Cited by 54
Drenan, R. M., & Lester, H. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004671 · Cited by 55
Self-citationZhang, D., Mallela, A., Sohn, D., Carroll, F. I., Bencherif, M., Letchworth, S. R., & Quik, M. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207639 · Cited by 49
Self-citationNicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior
Cohen, B. N., Mackey, E. D. W., Grady, S. R., McKinney, S. L., Patzlaff, N. E., Wageman, C. R., McIntosh, J. M., Marks, M. J., Lester, H. A., & Drenan, R. M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.047 · Cited by 50
Self-citationBrunzell, D. H., McIntosh, J. M., & Papke, R. L. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12421 · Cited by 43
Anderson, S. M., & Brunzell, D. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048665 · Cited by 41
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bağdaş, D., Alkhlaif, Y., Jackson, A. B., Carroll, F. I., Ditre, J. W., & Damaj, M. I. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.025 · Cited by 42
Hashimoto, T., Ichiki, T., Watanabe, A., Hurt‐Camejo, E., Michaëlsson, E., Ikeda, J., Inoue, E., Matsuura, H., Tokunou, T., Kitamoto, S., et al. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.03.006 · Cited by 39
Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake
Shariff, M. R., Quik, M., Holgate, J. Y., Morgan, M., Patkar, O. L., Tam, V., Belmer, A., & Bartlett, S. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150270 · Cited by 40
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse
Skike, C. E. V., Maggio, S. E., Reynolds, A. R., Casey, E. M., Bardo, M. T., Dwoskin, L. P., Prendergast, M., & Nixon, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.004 · Cited by 43
Xiao, C., Srinivasan, R., Drenan, R. M., Mackey, E. D. W., McIntosh, J. M., & Lester, H. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.005 · Cited by 37
Self-citationRollema, H., & Hurst, R. S. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4921-9 · Cited by 42
Engle, S. E., McIntosh, J. M., & Drenan, R. M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.014 · Cited by 33
Self-citationCell‐Derived Vesicles for Single‐Molecule Imaging of Membrane Proteins
Moonschi, F. H., Effinger, A. K., Zhang, X., Martin, W. E., Fox-Loe, A. M., Heidary, D. K., DeRouchey, J. E., & Richards, C. I. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201408707 · Cited by 32
Brunzell, D. H. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts089 · Cited by 36
Berry, J. N., Engle, S. E., McIntosh, J. M., & Drenan, R. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.052 · Cited by 32
Self-citationPerez, X. A., Khroyan, T. V., McIntosh, J. M., & Quik, M. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.105 · Cited by 30
Henderson, B. J., Carper, D. J., González-Cestari, T. F., Yi, B., Mahasenan, K. V., Pavlovicz, R. E., Dalefield, M. L., Coleman, R. S., Li, C., & McKay, D. B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201294r · Cited by 30
Graupner, M., Maex, R., & Gutkin, B. S. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003183 · Cited by 30
Mello, N. K., Fivel, P. A., Kohut, S. J., & Carroll, F. I. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.325 · Cited by 26
de Moura, F. B., & McMahon, L. R. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4514-4 · Cited by 29
Bolchi, C., Gotti, C., Binda, M., Fumagalli, L., Pucci, L., Pistillo, F., Vistoli, G., Valoti, E., & Pallavicini, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200937t · Cited by 27
Liu, W., & Li, M. D. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170801103009 · Cited by 28
Feng, B., Xing, J.-H., Jia, D., Liu, S., Guo, H.-J., Li, X., He, X., & Zhao, M. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.040 · Cited by 27
Wen, L., Yang, Z., Cui, W., & Li, M. D. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.103 · Cited by 27
Arias, H. R., Feuerbach, D., Targowska‐Duda, K. M., Kaczor, A. A., Poso, A., & Jóźwiak, K. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.11.003 · Cited by 25
Nicotinic acetylcholine receptors: Key targets for attenuating neurodegenerative diseases
Bye, L. J., Finol‐Urdaneta, R. K., Tae, H., & Adams, D. J. (2023) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2023.106387 · Cited by 28
Lacroix, F., Pettorelli, A., Maddux, J.-M. N., Heidari-Jam, A., & Chaudhri, N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.254 · Cited by 24
Bordia, T., McIntosh, J. M., & Quik, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12179 · Cited by 23
Chronic treatment with varenicline changes expression of four nAChR binding sites in mice
Marks, M. J., O’Neill, H. C., Wynalda, K., Ortiz, N. C., Simmons, E. E., Short, C. A., Butt, C. M., McIntosh, J. M., & Grady, S. R. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.019 · Cited by 23
Self-citationOrtiz, N. C., O'Neill, H. C., Marks, M. J., & Grady, S. R. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr284 · Cited by 22
Self-citationUnderstanding the Role α7 Nicotinic Receptors Play in Dopamine Efflux in Nucleus Accumbens
Maex, R., Grinevich, V. P., Grinevich, V. P., Budygin, E. A., Bencherif, M., & Gutkin, B. S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500126t · Cited by 23
Self-citationLocal Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
Engle, S. E., Broderick, H. J., & Drenan, R. M. (2012) · Journal of Visualized Experiments · doi:10.3791/50034 · Cited by 24
Self-citationWaeiss, R. A., Knight, C. P., Hauser, S. R., Pratt, L. A., McBride, W. J., & Rodd, Z. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5174-y · Cited by 22
Farhat, S. M., Mahboob, A., & Ahmed, T. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1587452 · Cited by 20
Cunningham, C. S., & McMahon, L. R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3037-5 · Cited by 19
Neonicotinic analogues: Selective antagonists for α4β2 nicotinic acetylcholine receptors
Faundez‐Parraguez, M., Farias-Rabelo, N., González-Gutiérrez, J. P., Etcheverry-Berríos, Á., Alzate‐Morales, J. H., Adasme‐Carreño, F., Varas, R., Bermúdez, I., & Iturriaga‐Vásquez, P. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.024 · Cited by 19
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline
Schassburger, R. L., Levin, M. E., Weaver, M. T., Palmatier, M. I., Caggiula, A. R., Donny, E. C., & Sved, A. F. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3732-x · Cited by 19
Rodriguez, J. S., Cunningham, C. S., de Moura, F. B., Ondachi, P. W., Carroll, F. I., & McMahon, L. R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3589-z · Cited by 15
Wageman, C. R., Marks, M. J., & Grady, S. R. (2013) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntt146 · Cited by 16
Self-citationBarrett, S. T., Geary, T. N., Steiner, A. N., & Bevins, R. A. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000404 · Cited by 18
Breining, S. R., Melvin, M. S., Bhatti, B. S., Byrd, G. D., Kiser, M. N., Hepler, C. D., Hooker, D. N., Zhang, J., Reynolds, L. A., Benson, L. R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011299 · Cited by 15
Self-citationMolgó, J., Aráoz, R., Benoit, É., & Iorga, B. I. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.822365 · Cited by 14
Secondary Ammonium Agonists Make Dual Cation-π Interactions in α4β2 Nicotinic Receptors
Post, M. R., Tender, G. S., Lester, H. A., & Dougherty, D. A. (2017) · eNeuro · doi:10.1523/eneuro.0032-17.2017 · Cited by 14
Self-citationHenderson, B. J., González-Cestari, T. F., Yi, B., Pavlovicz, R. E., Boyd, R. T., Li, C., Bergmeier, S. C., & McKay, D. B. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300035f · Cited by 12
Touchette, J. C., Maertens, J. J., Mason, M. M., O’Rourke, K. Y., & Lee, A. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.019 · Cited by 13
The interpeduncular nucleus blunts the rewarding effect of nicotine
Jehl, J., Ciscato, M., Vicq, É., Guyon, N., de la Bâtie, G. D., Mondoloni, S., Frangieh, J., Mohayyaei, M., Nguyen, C., Pons, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2025.03.035 · Cited by 12
Altered nicotine reward-associated behavior following α4 nAChR subunit deletion in ventral midbrain
Peng, C., Engle, S. E., Yan, Y., Weera, M. M., Berry, J. N., Arvin, M. C., Zhao, G., McIntosh, J. M., Chester, J. A., & Drenan, R. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182142 · Cited by 14
Self-citationMoonschi, F. H., Fox-Loe, A. M., Fu, X., & Richards, C. I. (2018) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2825 · Cited by 12
Madsen, H. B., Koghar, H. S., Pooters, T., Massalas, J. S., Drago, J., & Lawrence, A. J. (2014) · Addiction Biology · doi:10.1111/adb.12148 · Cited by 15
Jackson, A. E., Silk, S., Buhidma, Y., & Shoaib, M. C. (2016) · Addiction Biology · doi:10.1111/adb.12423 · Cited by 12
McClure‐Begley, T. D., Wageman, C. R., Grady, S. R., Marks, M. J., McIntosh, J. M., Collins, A. C., & Whiteaker, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07759.x · Cited by 11
Self-citationRecent advances in gene manipulation and nicotinic acetylcholine receptor biology
Tammimäki, A., Horton, W. J., & Stitzel, J. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.014 · Cited by 10
Watanabe, A., Ichiki, T., Kojima, H., Takahara, Y., Hurt‐Camejo, E., Michaëlsson, E., Sankoda, C., Ikeda, J., Inoue, E., Tokunou, T., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.006 · Cited by 10
de Moura, F. B., & McMahon, L. R. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000233 · Cited by 8
Baroreflex deficiency aggravates atherosclerosis via α7 nicotinic acetylcholine receptor in mice
Chen, L., Liu, D., Zhang, X., Zhang, E.-H., Liu, C., Su, D., & Cai, G. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.08.008 · Cited by 9
The role of nicotinic receptors in alcohol consumption
Kamens, H. M., Flarend, G., & Horton, W. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106705 · Cited by 8
Post, M. R., Limapichat, W., Lester, H. A., & Dougherty, D. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.009 · Cited by 8
Self-citationTC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors
Wall, T. R., Henderson, B. J., Voren, G., Wageman, C. R., Deshpande, P., Cohen, B. N., Grady, S. R., Marks, M. J., Yohannes, D., Kenny, P. J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00641 · Cited by 8
Self-citationElucidating the reinforcing effects of nicotine: a tribute to Nadia Chaudhri
Sved, A. F., Caggiula, A. R., & Donny, E. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06266-7 · Cited by 7
Cell‐Derived Vesicles for Single‐Molecule Imaging of Membrane Proteins
Moonschi, F. H., Effinger, A. K., Zhang, X., Martin, W. E., Fox-Loe, A. M., Heidary, D. K., DeRouchey, J. E., & Richards, C. I. (2014) · Angewandte Chemie · doi:10.1002/ange.201408707 · Cited by 6
Nicotine Administration Augments Abdominal Aortic Aneurysm Progression in Rats
Hadzikadunic, H., Sjælland, T. B., Lindholt, J. S., Steffensen, L. B., Beck, H. C., Kavaliūnaitė, E., Rasmussen, L. M., & Stubbe, J. (2023) · Biomedicines · doi:10.3390/biomedicines11051417 · Cited by 5
Fedorov, N. B., Benson, L., Graef, J. D., Hyman, J., Sollenberger, J., Pettersson, F., Lippiello, P. M., & Bencherif, M. (2012) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2012.02.005 · Cited by 5
Self-citationOndachi, P. W., Castro, A. H., Luetje, C. W., Wageman, C. R., Marks, M. J., Damaj, M. I., Mascarella, S. W., Navarro, H. A., & Carroll, F. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00107 · Cited by 5
Self-citationα6 nicotinic acetylcholine receptors: A pharmacological challenge with untapped therapeutic promise
Zhang, B., Mao, K., Ma, L., Chen, Y.-S., Ren, M., Xiong, Y., Zhangsun, D., Dong, S., Luo, S., & Gao, B. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118300 · Cited by 3
Flow-cell radionuclide analysis
L’Annunziata, M. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814395-7.00010-6 · Cited by 3
Ogunjirin, A. E., Fortunak, J., Brown, L. L., Xiao, Y., & Dávila‐García, M. I. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1705-z · Cited by 3
L’Annunziata, M. F. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384873-4.00017-7 · Cited by 3
Cunningham, C. S., Moerke, M. J., Javors, M. A., Carroll, F. I., & McMahon, L. R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13635 · Cited by 2
de Moura, F. B., & McMahon, L. R. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000452 · Cited by 3
Trigo, J. M., & Foll, B. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_11 · Cited by 3
Holtyn, A. F., Davis, C. M., & Weerts, E. M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107665 · Cited by 2
Enhancement of Opioid Antinociception by Nicotinic Ligands
de Moura, F. B., & Bergman, J. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000423 · Cited by 2
The discriminative stimulus effects of epibatidine in C57BL/6J mice
de Moura, F. B., Hiranita, T., & McMahon, L. R. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000555 · Cited by 1
Murayama, M. A. (2022) · Translational and Regulatory Sciences · doi:10.33611/trs.2021-028 · Cited by 1
Contribution of Variants in CHRNB3/A6 Gene Cluster on Chromosome 8 to Smoking Dependence
Li, M. D. (2018) · Springer eBooks · doi:10.1007/978-981-10-7530-8_6 · Cited by 1
Barrett, S. T. (2014) · Lincoln (University of Nebraska)
Sheppard, A. B. (2014) · Digital Commons - East Tennessee State University (East Tennessee State University)
Nicotinic Acetylcholine Receptors in Alzheimer’s and Parkinson’s Disease
Dineley, K. T. (2014) · The Receptors · doi:10.1007/978-1-4939-1167-7_19
Qi, X., Bruijnzeel, D. M., & Bruijnzeel, A. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802574-1.00010-7
The Effects of Binge-Like Sucrose Consumption on the Mesolimbic Reward Pathway in the Brain
Shariff, M. R. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.107900
Tarren, J. R. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.118142
Hoang, M. (2020) · TSpace (University of Toronto)
Metadata
- Authors
- Grady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., & Marks, M. J.
- Affiliations
- University of Colorado Boulder (US)
- California Institute of Technology (US)
- Corresponding author
- Grady, Sharon R.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 58
- Issue
- 7
- Pages
- 1054-1066
- ISSN
- 0028-3908 (ISSN-L)
- PMC
- PMC2849849
- OpenAlex
- W2068493106
- Cited by
- 98
- References
- 50
- Citations by year
- 2025: 1 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 9 · 2017: 6 · 2016: 10 · 2015: 9 · 2014: 15 · 2013: 10 · 2012: 12
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- National Institute on Drug Abuse (U19DA019375, DA 015663, R01DA017279, P30DA015663)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- nicotinic acetylcholine receptors, receptor subtype selectivity, alpha4beta2 receptor, alpha7 nicotinic acetylcholine receptor, nicotinic agonists, partial agonists, dopamine release, GABA release, smoking cessation aids, steric bulk, receptor binding affinity
- MeSH terms
- Animals, Body Temperature, Brain, Cell Line, Drug Evaluation, Preclinical, Elasticity, Mice, Transgenic, Protein Conformation, Pyridines, Receptors, Nicotinic, Synaptosomes, Molecular Structure, Mice, Knockout, Nicotinic Agonists, Nicotinic Antagonists, Mice, Gene Knock-In Techniques, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
